• Explore /
  • Poster
  • / Real-world effectiveness of PARP inhibitors (PARPi) in metastatic castration-resistant prostate cancer (mCRPC) by genomic homologous recombination repair (HRR) alterations and homologous recombination deficiency signature (HRDsig).

Real-world effectiveness of PARP inhibitors (PARPi) in metastatic castration-resistant prostate cancer (mCRPC) by genomic homologous recombination repair (HRR) alterations and homologous recombination deficiency signature (HRDsig).

Abstract Poster

Authors

null

Daniel Triner

Department of Urology, Michigan Medicine, Ann Arbor, MI

Daniel Triner , Ryon Graf , Ole Gjoerup , Hanna Tukachinsky , Jeffrey S. Ross , Heather H. Cheng , Colin C. Pritchard , Amado J. Zurita , Joaquin Mateo , Marcin Cieslik , Todd Matthew Morgan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Translational Research, Tumor Biology, Biomarkers, and Pathology

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 186)

DOI

10.1200/JCO.2024.42.4_suppl.186

Abstract #

186

Poster Bd #

H15

Abstract Disclosures

Similar Posters

First Author: Jonathan Poh

First Author: Qiuxiang Ou

Poster

2023 ASCO Annual Meeting

The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?

The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?

First Author: Muhammad Danyal Ahsan

First Author: Severine Guiu Lahaye